The U.S. Meals and Drug Administration (FDA) has accepted PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to assist establish sufferers with epithelial...
Minimal residual illness, or MRD, testing might have the potential to supply peace of thoughts to survivors of breast most cancers, as a survivor and...
The addition of the oral AKT inhibitor Truqap (capivasertib) to Zytiga (abiraterone acetate), prednisone and androgen deprivation remedy (ADT) prolonged investigator-assessed radiographic...
Amongst sufferers with high-risk, HER2-positive main breast most cancers with residual invasive illness following neoadjuvant remedy, remedy with Enhertu (fam-trastuzumab deruxtecan-nxki; T-DXd)...
Amongst sufferers domestically superior, unresectable, stage 3 non-small cell lengthy most cancers (NSCLC) that has not progressed after platinum-based concurrent chemoradiation (cCRT),...
Sufferers with beforehand handled, regionally superior or metastatic hormone receptor (HR)-positive, HER2-negative breast most cancers skilled superior progression-free survival when handled with...
Amongst sufferers with high-risk, HER2-positive early breast most cancers, presurgical, or neoadjuvant, remedy with Enhertu (fam-trastuzumab deruxtecan-nxki; T-DXd) adopted by paclitaxel, Herceptin...
